Kazia Therapeutics Limited (NASDAQ:KZIA – Free Report) shares are going to reverse split on Monday, October 28th. The 1-10 reverse split was announced on Tuesday, October 15th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, October 25th.
Kazia Therapeutics Price Performance
Shares of Kazia Therapeutics stock opened at $0.33 on Wednesday. The company’s fifty day simple moving average is $0.38 and its two-hundred day simple moving average is $0.35. Kazia Therapeutics has a 12-month low of $0.19 and a 12-month high of $1.58.
Analysts Set New Price Targets
Separately, HC Wainwright reaffirmed a “buy” rating and set a $2.00 price objective on shares of Kazia Therapeutics in a research report on Friday, July 12th.
Kazia Therapeutics Company Profile
Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma.
Recommended Stories
- Five stocks we like better than Kazia Therapeutics
- How to Most Effectively Use the MarketBeat Earnings Screener
- Goldman Sachs Earnings Reveal Market Moves Investors Can’t Ignore
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- AMD Gains Momentum With AI: Can It Beat Expectations?
- Stock Market Upgrades: What Are They?
- Lithium Grab: 2 Lithium Stocks That Could Be Takeover Targets
Receive News & Ratings for Kazia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kazia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
